ipilimumab,nivolumab
bms
['ipilimumab', 'nivolumab', 'nsclc', 'nivo', 'sclc']
#asco22 june 6, 8 am ct, hall a, poster 13: lcrf scientific advisory board member dr. julie brahmer will present a poster session on 5-year survival outcomes with nivolumab + ipilimumab vs. chemo as first-line treatment for metastatic nsclc. 
Working to improve and save lives by funding groundbreaking research for the prevention, diagnosis, treatment and cure of lung cancer.